Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Mar 2, 2026 • 25min
Combination Approaches in PD-L1–Positive Metastatic Triple Negative Breast Cancer
Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metastatic TNBC, the implications of recent trials like ASCENT-04, and the potential of antibody-drug conjugates (ADCs) such as sacituzumab govitecan and datopotamab deruxtecan.
Key topics included:
• The role of PD-L1 positivity in treatment decisions
• Insights from the ASCENT-04 trial and its findings
• Common side effects associated with sacituzumab and strategies for management
• The future of immunotherapy and ADCs in TNBC treatment
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable information and clinical pearls. Don't forget to subscribe for more insightful discussions on cancer treatment!
#TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers
Feb 25, 2026 • 18min
HER2+ Breast Cancer Treatment Algorithm: Dr. Virginia Kaklamani
In this episode of the Oncology Brothers podcast, we dived deep into the evolving landscape of HER2-positive breast cancer treatment following the significant advancements made in 2025. Joined by Dr. Virginia Kaklamani from UT Health San Antonio, we discussed the latest data from SABCS 2025 and pivotal trials such as DESTINY-Breast09, which have led to new treatment approvals and strategies.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Key topics included:
• The treatment algorithm for early-stage HER2-positive breast cancer, including the APT trial and the role of trastuzumab.
• Insights into neoadjuvant and adjuvant therapies, including the implications of the neoCARHP trial regimen and the potential of T-DXd.
• The impact of recent studies in metastatic HER2-positive disease, including the approval of T-DXd plus pertuzumab and the promising results from the PATINA trial.
• A discussion on managing side effects and the importance of patient quality of life during treatment.
Join us for an informative conversation that highlights the latest advancements in HER2-positive breast cancer care and how they can be applied in clinical practice. Don't forget to like, subscribe, and leave a review to help us reach more healthcare professionals who can benefit from these discussions!
#HER2Positive, #BreastCancer, #SABCS25, #TDXd, #BreastCancerTreatment, #OncologyBrothers
Feb 19, 2026 • 22min
Metastatic Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Kevin Kalinsky
In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity management.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• YouTube: https://www.youtube.com/@oncologybrothers
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
The discussion covered:
• The critical role of NGS testing (tissue vs. liquid biopsy) in identifying PIK3CA, ESR1, AKT1 and PTEN alterations.
• Frontline management of high-risk, endocrine-resistant disease with the inavolisib triplet (INAVO120) and its overall survival benefit.
• Choosing between CDK4/6 inhibitors (abemaciclib vs. ribociclib) in de novo metastatic disease.
• Post-CDK4/6 inhibitors on progression we covered, the use of oral SERDs (imlunestrant) and AKT inhibitors (capivasertib).
• The "ADC explosion", sequencing T-DXd (DESTINY-Breast06), sacituzumab govitecan (TROPiCS-02), and datopotamab deruxtecan (TROPION-Breast01).
• Clinical pearls for managing toxicities: stomatitis, hyperglycemia, rash, neutropenia, and ILD.
Join us as we break down the latest data and provide actionable insights for the practicing oncologist. Don't forget to subscribe for more episodes in our breast cancer algorithm series!
#MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers
Feb 12, 2026 • 27min
Early Stage Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Erica Mayer
In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain dived deep into the evolving landscape of breast cancer treatment algorithms, focusing on early and locally advanced hormone receptor-positive breast cancer. Joined by Dr. Erica Mayer, a breast medical oncologist at the Dana-Farber Cancer Institute.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• YouTube: https://www.youtube.com/@oncologybrothers/
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
The discussion covered:
• The role of chemotherapy in early-stage hormone receptor-positive breast cancer, including the use of anthracyclines versus taxane-based approaches.
• Insights from the TAILORx trial and the implications of Oncotype DX scores in treatment decisions.
• The ongoing OFSET trial and its potential impact on premenopausal patients with low recurrence scores.
• The use of CDK4/6 inhibitors, including ribociclib and abemaciclib, in the adjuvant setting, along with their side effect profiles and dosing considerations.
• The significance of the recent lidERA trial results featuring giredestrant and its implications for future treatment strategies.
Join us as we explore the latest data, treatment paradigms, and the importance of patient-shared decision-making in breast cancer care. Don't forget to subscribe for more insights and staying up to date in the field of cancer.
#EarlyBreastCancer, #OncotypeDX, #CDK46inhibitors, #OralSERD, #AdjuvantTherapy, #OncologyBrothers
Feb 9, 2026 • 22min
Current & Future Role of Anktiva (N-803): Dr. Patrick Soon-Shiong
In this episode of the Oncology Brothers podcast, we engaged in a thought-provoking discussion with Dr. Patrick Soon-Shiong, a pioneer in oncology and the innovator behind the approval of nab-paclitaxel (Abraxane). We delved into the exciting potential of Anktiva (N-803), an IL-15 receptor super agonist designed to expand and activate natural killer (NK) cells and CD8 T cells, with the hope of revolutionizing cancer treatment.
Dr. Soon-Shiong shared insights into the mechanism of action of Anktiva, its current approvals in non-muscle invasive bladder cancer, and extended approval in non-small cell lung cancer in Saudi Arabia, and the promising clinical trial data that suggests a significant increase in overall survival for patients. The conversation also touched on the importance of restoring lymphocyte counts and the implications for treating various tumor types.
Join us as we explore the future of immunotherapy, the challenges of regulatory approval, and the potential for Anktiva to change the landscape of cancer treatment.
Key Topics:
• Mechanism of action of Anktiva
• Current approvals and clinical trial data
• The role of lymphocyte counts in cancer treatment
• Future directions for immunotherapy
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more discussions on the latest in oncology!
#Oncology #CancerTreatment #Immunotherapy #IL15Agonist #OncologyBrothers
Feb 5, 2026 • 23min
Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56.
Key topics included:
• The design and findings of the DESTINY-Breast09 trial
• Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane)
• The implications of these findings for clinical practice
• The role of maintenance therapy and the potential for personalized treatment strategies
• Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease)
Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!
#HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers
Feb 3, 2026 • 27min
Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver
In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option.
Episode Highlights:
• Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments.
• In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics.
• Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects.
• Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations.
• Practical considerations for administering these treatments in both inpatient and outpatient settings.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals!
#AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers
Jan 26, 2026 • 24min
Head & Neck Cancers Treatment Landscape & Algorithm – Dr. Fangdi Sun
In this episode of the Oncology Brothers podcast, we dived into the current treatment landscape for head and neck cancer. We welcomed Dr. Fangdi Sun, a head and neck medical oncologist from Stanford University, to discuss key topics including:
• The importance of initial workup and the role of biomarkers, including HPV and EBV testing.
• Treatment paradigm for early-stage and locally advanced head and neck cancers, focusing on the differences between HPV-positive and HPV-negative disease.
• The evolving role of immunotherapy and the new perioperative approaches in treatment.
• Insights into managing metastatic disease, including the use of PD-L1 scores and systemic therapy options.
• The significance of multidisciplinary collaboration in optimizing patient care.
Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the complexities of head and neck cancer treatment. Don't miss out on this informative discussion!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe to our channel for more episodes as we continue to bridge the gap in oncology!
#HeadAndNeckCancer, #HPV, #Immunotherapy, #MultidisciplinaryCare, #OncologyBrothers
Jan 22, 2026 • 22min
FDA Approval of Daratumumab in High Risk Smoldering Myeloma: AQUILA by Dr. Vincent Rajkumar
In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention.
Key topics discussed included:
• The definition and classification of smoldering myeloma
• The design and findings of the AQUILA trial
• The significance of time to progression and overall survival in treatment
• The risk-benefit analysis of daratumumab therapy, including potential side effects
• Future directions in myeloma treatment and ongoing research
Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!
Jan 19, 2026 • 25min
ASH 2025 Multiple Myeloma Highlights – AQUILA, COBRA, TecLILLE, MajesTEC-3: Dr. Ben Derman
Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond.
In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-head comparisons in newly diagnosed disease, and finally, to the groundbreaking bispecific antibody data that is set to revolutionize care at first relapse.
Key topics covered in this episode:
● AQUILA update: Daratumumab in high-risk smoldering myeloma, and the ongoing clinical dilemma
● COBRA: Is KRD superior to VRD in newly diagnosed multiple myeloma? Unpacking the MRD and PFS data.
● TecLILLE: A first look at Teclistamab + Daratumumab in frontline, transplant-ineligible patients.
● MajesTEC-3: PFS and OS data for Teclistamab + Daratumumab in first relapse, and its impending FDA approval.
Tune in for this expert breakdown to navigate the new myeloma landscape with confidence.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe for more deep dives into treatment algorithms and major conference highlights!
#OncologyBrothers #ASH2025 #MultipleMyeloma #Myeloma #SmolderingMyeloma #BispecificAntibody #Teclistamab #Daratumumab #CART
